Journals / Turkish Journal of Pediatrics / 2019 / Cilt: 61 - Sayı: 5

Cardiometabolic risk factors in Turkish children with hepatosteatosis

Pages
714–722
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The presence and grade ofhepatosteatosis on ultrasound can be used as surrogate markers of MS andCM risk in children.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:We aimed to investigate the prevalence of cardiometabolic (CM) risk factors(impaired fasting glucose (>100 mg/dL), high blood pressure, overweight orobesity, high serum triglycerides (TG) and low serum high-density lipoproteincholesterol levels) in children with hepatosteatosis detected by abdominalultrasound.
📊
Key Findings & Data:Presence of≥3 risk factors was defined as metabolic syndrome (MS).One hundred and forty-eight children and adolescents (67 boys, 81girls, andmean age 12.1±2.7 years) with hepatosteatosis were included.
💡
Conclusion & Impact:The presence and grade ofhepatosteatosis on ultrasound can be used as surrogate markers of MS andCM risk in children.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

We aimed to investigate the prevalence of cardiometabolic (CM) risk factors(impaired fasting glucose (>100 mg/dL), high blood pressure, overweight orobesity, high serum triglycerides (TG) and low serum high-density lipoproteincholesterol levels) in children with hepatosteatosis detected by abdominalultrasound. Children whom ultrasound examination revealed hepatic steatosiswere included in the study. Medical records, anthropometric and biochemicalparameters were reviewed for the presence of the CM risk factors. Presence of≥3 risk factors was defined as metabolic syndrome (MS).One hundred and forty-eight children and adolescents (67 boys, 81girls, andmean age 12.1±2.7 years) with hepatosteatosis were included. Sonographichepatosteatosis grades of 1, 2 and 3 were observed in 111 (75%), 33 (22.3%),and 4 (2.7%) subjects, respectively. MS was observed in 36 patients (24.3%).The number of CM risk factors and degree of hepatic steatosis were correlated(r=0.183, p=0.026). Serum TG levels in girls and age in boys were significantlyassociated with the presence of medium to severe hepatosteatosis (grades 2 or3) (R2=.342, =.040 and R2=.538, p=.001, respectively). CM risk factors andMS are common in children with hepatosteatosis. The presence and grade ofhepatosteatosis on ultrasound can be used as surrogate markers of MS andCM risk in children.

🔖

Cite This Article

ASLAN, A., ERDEMLİ, S., GÜNAYDIN, G. D., ASLAN, M., YAZAR, R. Ö., KABAALİOĞLU, A., AĞIRBAŞLI, M. A. (2019). Cardiometabolic risk factors in Turkish children with hepatosteatosis. Turkish Journal of Pediatrics, Cilt: 61 - Sayı: 5, 714–722. https://ajindex.com/articles/412075

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. McGill HC Jr, McMahan CA, Gidding SS. Preventing heart disease in the 21st century: implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study. Circulation 2008; 117: 1216- 1217
  2. Tanrikulu MA, Agirbasli M, Berenson G. Primordial prevention of cardiometabolic risk in childhood. Adv Exp Med Biol 2017; 956: 489-496
  3. Agirbasli M, Tanrikulu AM, Berenson GS. Metabolic syndrome: bridging the gap from childhood to adulthood. Cardiovasc Ther 2016; 34: 30-36
  4. Morrison JA, Friedman LA, Gray-McGuire C. Metabolic syndrome in childhood predicts adult cardiovascular disease 25 years later: the Princeton Lipid Research Clinics Follow-up Study. Pediatrics 2007; 120: 340-345
  5. Al-Hamad D, Raman V. Metabolic syndrome in children and adolescents. Transl Pediatr 2017; 6: 397- 407
  6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in adults (Adult Treatment Panel III. JAMA 2001; 285: 2486-2497
  7. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999; 16: 442-443
  8. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet 2005; 366: 1059- 1062
  9. Agirbasli M, Adabag S, Ciliv G. Secular trends of blood pressure, body mass index, lipids and fasting glucose among children and adolescents in Turkey. Clin Obes 2011; 1: 161-167
  10. Fu JF, Shi HB, Liu LR, et al. Non-alcoholic fatty liver disease: an early mediator predicting metabolic syndrome in obese children? World J Gastroenterol 2011; 17: 735-742
  11. Di Sessa A, Umano GR, Miraglia Del Giudice E. The association between non-alcoholic fatty liver disease and cardiovascular risk in children. Children (Basel) 2017; 4: E57
  12. Sass DA, Chang P, Chopra KB. Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci 2005; 50: 171-180
  13. Charatcharoenwitthaya P, Lindor KD. Role of radiologic modalities in the management of nonalcoholic steatohepatitis. Clin Liver Dis 2007; 11: 37-54
  14. Machado MV, Cortez-Pinto H. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol 2013; 58: 1007-1019
  15. Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reli